Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics

Rifkin, Robert M.; Abonour, Rafat; Terebelo, Howard R.; Shah, Jatin J.; Gasparetto, Cristina; Hardin, James W.; Srinivasan, Shankar; Ricafort, Rosanna; Nagarwala, Yasir M.; Durie, Brian G.M.

doi:10.1016/j.clml.2014.12.002

Cited by 30 publications

(30 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In common with other reports (Kyle et al, 2003;Durie, 2011), the majority of patients (61%) in our study had bone pain at diagnosis. The prevalence of renal dysfunction (20%) was also in line with other studies (Kyle et al, 2003;Rifkin et al, 2015). In general, the prevalence of anaemia at diagnosis is reported to be about 70% (Kyle et al, 2003;Birgegard et al, 2006) whereas this was much lower in our study (39%) and closer to the prevalence (45%) reported in a recent registry study in the USA (Rifkin et al, 2015).…”

Section: Discussionsupporting

confidence: 92%

Multiple myeloma: patient outcomes in real‐world practice

et al. 2016

View full text Add to dashboard Cite

SummaryWith increasing number of therapies available for the treatment of multiple myeloma, it is timely to examine the course of patients' journeys. We investigated patient characteristics, treatment durations and outcomes, and symptom burden across the treatment pathway in Belgium, France, Germany, Italy, Spain, Switzerland and the UK. In total, 435 physicians retrospectively reviewed 4997 patient charts. Profiles of patients diagnosed with multiple myeloma during the last 12 months were similar across countries; bone pain was the most common presentation. Median duration of first‐line therapy was 6 months, followed by a median treatment‐free interval of 10 months; both these decreased with increasing lines of therapy, as did time to progression. Depth of response, as assessed by the treating physician, also decreased with each additional line of therapy: 74% of patients achieved at least a very good partial response at first line, compared with only 11% at fifth line. Deeper responses were associated with longer time to progression, although these were physician‐judged. Toxicities and co‐morbidities increased with later treatment lines, and were more likely to have led to discontinuation of treatment. These real‐world data provide an insight into patient outcomes and treatment decisions being made in clinical practice.

show abstract

Section: Discussionsupporting

confidence: 92%

Multiple myeloma: patient outcomes in real‐world practice

et al. 2016

View full text Add to dashboard Cite

show abstract

“…10 The registry comprises 2 cohorts: cohort 1 (n 5 1493) includes patients enrolled from September 2009 to December 2011, and cohort 2 (n 5 1518) includes patients enrolled from December 2012 to April 2016. Patients are treated with therapies (including maintenance) at physician discretion.…”

Section: Methodsmentioning

confidence: 99%

“…The registry was designed to examine diagnostic patterns, treatment choices and sequencing, clinical outcomes, and quality of life in patients with NDMM. 9,10 Here, data from the Connect MM Registry were used to investigate the impact of maintenance therapy on long-term outcomes in ASCT-eligible patients with NDMM who were treated from 2009 to 2011.…”

Section: Introductionmentioning

confidence: 99%

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Full study design details have been previously described. [11] SPM were defined as new (or recurrent after 45 years) cancers, including invasive and non-invasive (non-melanoma skin cancers), occurring after MM diagnosis and at any time during study follow-up regardless of causal relationship to MM therapy. This report focuses only on invasive SPM (categorized as a hematologic or solid tumor).…”

mentioning

confidence: 99%